ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · IEX Real-Time Price · USD

1.270

-0.020 (-1.55%)

Apr 17, 2024, 4:30 PM EDT - Market closed

ImmunoPrecise Antibodies Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Year	2023	2022	2021	2020	2019
Revenue	20.67	19.36	17.91	14.06	10.93
Revenue Growth (YoY)	6.72%	8.11%	27.41%	28.66%	-
Cost of Revenue	9.1	8.38	6.37	6.02	5.63
Gross Profit	11.56	10.98	11.54	8.03	5.29
Selling, General & Admin	23.42	18.06	8	6.52	5.69
Research & Development	12.28	7.66	1.97	0.45	0.49
Other Operating Expenses	4.41	2.01	8.48	5.16	5.35
Operating Expenses	40.11	27.73	18.46	12.13	11.52
Operating Income	-28.55	-16.75	-6.92	-4.09	-6.23
Interest Expense / Income	0	0	0.52	0.54	0.41
Other Expense / Income	-0.8	-0.9	-1.44	0.66	0.97
Pretax Income	-27.75	-15.85	-6	-5.29	-7.61
Income Tax	-1.19	0.86	1.35	-0.35	0
Net Income	-26.56	-16.71	-7.34	-4.95	-7.62
Shares Outstanding (Basic)	25	20	16	14	13
Shares Outstanding (Diluted)	25	20	16	14	13
Shares Change	26.46%	19.51%	20.88%	8.67%	-
EPS (Basic)	-1.07	-0.85	-0.45	-0.36	-0.60
EPS (Diluted)	-1.07	-0.85	-0.45	-0.36	-0.60
Free Cash Flow	-21.33	-11.18	-2.03	-1.97	-3.85
Free Cash Flow Per Share	-0.86	-0.57	-0.12	-0.14	-0.31
Gross Margin	55.95%	56.72%	64.41%	57.15%	48.46%
Operating Margin	-138.16%	-86.49%	-38.63%	-29.12%	-56.99%
Profit Margin	-128.53%	-86.29%	-40.98%	-35.19%	-69.72%
Free Cash Flow Margin	-103.21%	-57.73%	-11.32%	-13.99%	-35.25%
EBITDA	-21.04	-11.99	-1.42	-0.45	-4.01
EBITDA Margin	-101.80%	-61.94%	-7.92%	-3.19%	-36.73%
Depreciation & Amortization	6.72	3.85	4.06	4.31	3.19
EBIT	-27.75	-15.85	-5.48	-4.76	-7.2
EBIT Margin	-134.29%	-81.84%	-30.58%	-33.83%	-65.89%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).